CEO says Pfizer not worried about expiring patents, generic competition

Pfizer rivals may be concerned about competition from generics, but the pharmaceutical firm is prepared to deal with the expiration of its patents on several major drugs over the next three years, CEO Henry McKinnell said. Other companies were hurt by expiring patents because they "failed to anticipate or lacked the means to respond," he said. McKinnell indicated Pfizer currently has as many as 20 drugs to submit for approval by the end of 2006.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC